Related Experiment Video
Updated: May 15, 2026
07:29
Intravascular Delivery of Biologics to the Rat Kidney
Published on: September 1, 2016
Biologics and the cardiovascular system: a double-edged sword
Camille Roubille1, Johanne Martel-Pelletier, Boulos Haraoui
1Osteoarthritis Research Unit, University of Montreal Hospital Research Center (CRCHUM), Notre-Dame Hospital, 1560 Sherbrooke Street East, Montreal, Quebec, Canada. camille.roubille@gmail.com
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
|January 5, 2013
Summary
Patients with inflammatory diseases face higher cardiovascular risks due to systemic inflammation. Biologics targeting inflammation show both beneficial and detrimental effects on heart health, impacting atherosclerosis and heart failure.
Area of Science:
- Cardiovascular Medicine
- Rheumatology
- Immunology
Background:
- Chronic inflammatory diseases, like rheumatoid arthritis, elevate cardiovascular disease (CVD) risk.
- Systemic inflammation, driven by cytokines (TNF-alpha, IL-1, IL-6), independently accelerates atherosclerosis and contributes to heart failure (HF).
Purpose of the Study:
- To review the cardiovascular and vascular effects of biologics used in inflammatory conditions.
- To analyze the impact of TNF-alpha, IL-6, IL-1, and anti-CD20 blockade on cardiovascular outcomes.
Main Methods:
- Literature review of studies on biologics in inflammatory arthritis and vasculitides.
- Analysis of clinical data and research on biologic mechanisms affecting cardiovascular and non-cardiac conditions.
Main Results:
- Biologics targeting pro-inflammatory cytokines have shown both positive and negative effects on cardiovascular health.
- Specific biologics influence atherosclerosis, myocardial infarction, cerebrovascular disease, and heart failure progression.
Conclusions:
- Understanding the dual effects of biologics is crucial for managing cardiovascular risk in patients with inflammatory diseases.
- Targeted biologic therapies require careful consideration of their cardiovascular implications.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:19Factors Affecting Drug Biotransformation: Biological
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:28Biopharmaceutics and Pharmacokinetics: Overview
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...